A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either ...
– GEN’s Editor-in-Chief, John Sterling, interviews Jeffery Stevenson, Ph.D., ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results